NEWS
Our Latest News
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
Private equity healthcare specialist ARCHIMED announces the sale of DIESSE to private equity firm Fremman Capital. The transaction caps a five-year partnership with DIESSE and marks the latter’s transformation into a leading clinical diagnostics innovator. The deal returns 4.6 times invested capital to shareholders.
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
January
27,
2025
ARCHIMED earns 5x its investment, selling a majority of Ad-Tech to Tokyo-listed Nihon Kohden
November
26,
2024
ARCHIMED acquires SeqCenter, a fast-growing player in cutting-edge DNA and RNA gene sequencing
November
8,
2024
368